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γδ T cells possess cytotoxic antitumor activity mediated by production of proinflammatory 
cytokines, direct cytotoxic activity, and regulation of the biological functions of other cell 
types. Hence, these features have prompted the development of therapeutic strategies 
in which γδ T cells agonists or ex vivo-expanded γδ T cells are administered to tumor 
patients. Several studies have shown that γδ T  cells are an important component of 
tumor-infiltrating lymphocytes in patients affected by different types of cancer and a recent 
analysis of ~18,000 transcriptomes from 39 human tumors identified tumor-infiltrating γδ 
T  cells as the most significant favorable cancer-wide prognostic signature. However, 
the complex and intricate interactions between tumor cells, tumor microenvironment 
(TME), and tumor-infiltrating immune cells results in a balance between tumor-promoting 
and tumor-controlling effects, and γδ T cells functions are often diverted or impaired by 
immunosuppressive signals originating from the TME. This review focuses on the dan-
gerous liason between γδ T cells and tumoral microenvironment and raises the possibility 
that strategies capable to reduce the immunosuppressive environment and increase the 
cytotoxic ability of γδ T cells may be the key factor to improve their utilization in tumor 
immunotherapy.
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THe TUMOR MiCROeNviRONMeNT (TMe)
Tumors develop in a composite and heterogeneous microenvironment consisting of endothelial 
cells, stromal cells, and immune cells; all of them act and cooperate either in direct or indirect way 
with tumor cells promoting tumor proliferation, invasion, and metastasis or actively interfering with 
its development.
It is well known that a large number of cells of both the innate and adaptive immune compartments 
are present at the tumor site since the early steps of cancer development, exerting immunosurveil-
lance (1) and controlling spontaneous neoplastic diseases (2), even though the composition and 
extent of the immune infiltrates consistently varies among individuals (3, 4).
Tumors are able to escape from the host immune system and take advantage on the presence 
of infiltrating immune cells by modifying their functions and creating a TME favorable to tumor 
progression. In fact, tumor-infiltrating immune cells, together with stromal cells and extracellular 
matrix create an inflammatory milieu responsible for tumor expansion and dissemination and for 
FigURe 1 | Schematic representation of tumor microenvironment. Cross-talk between immune and tumoral cells: (A) antitumoral role of infiltrating γδ T cells 
mediated by proinflammatory cytokines and cytotoxic activity, (B) inflammation induced by tumor-infiltrating immune cells, (C) immunosuppressive polarization  
of immune cells, and (D) tumor promotion and neoangiogenesis induced by tumor-infiltrating immune cells.
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tumor evasion. Tumor escape from the host immune response is 
promoted by its ability to actively subvert antitumor immunity by 
interfering with cell development, differentiation, migration, and 
cytotoxicity or from host immunosuppression.
Cancer-associated fibroblasts (CAFs) (5–8), myeloid-derived 
suppressor cells (MDSC), regulatory T cells (Tregs), type-2 mac-
rophages (M2 macrophages), tumor-associated neutrophils (9), 
inhibitory cytokines, and immune checkpoint receptors are com-
ponents of the immune system acting together with cancer cells, 
responsible for the subversion of antitumor immunity (10, 11) 
(Figure 1). We will discuss any of these TME components in the 
following sections.
Cancer-Associated Fibroblasts
Cancer-associated fibroblasts are key players in the generation of 
an immunosuppressive TME and consequently in the promotion 
of tumor evasion from immune surveillance. It is well known 
that high presence of CAFs in the context of the tumor has been 
correlated with poor prognosis in several malignancies, including 
lung (12) and colorectal cancers (13). The mechanisms used by 
CAF to induce tumoral growth and immune escape are different: 
(i) the production and the release of a large amount of immu-
nosuppressive cytokines and growth factors, such as interleukin 
(IL)-6 and IL-8, transforming growth factor (TGF)-β, vascular 
endothelial growth factor (VEGF), and insulin-like growth factor, 
that directly or indirectly influence the behavior of malignant cells 
(14) and (ii) the direct suppressor activity on T cell proliferation 
through regulatory molecules and immunosuppressive cytokines 
released by fibroblasts. In addition, the analysis of the expression 
of costimulatory molecules on CAF have showed that CD80 and 
CD86 are not expressed by CAFs or normal fibroblast while B7H1 
and B7DC, that bind programmed death-1 (PD-1) on activating 
T cells trasducing a negative signal inside the cells, are expressed 
by CAFs, but not by normal fibroblasts. In non-small cell lung 
cancer (NSCLC) patients, Nazareth et  al. have demonstrated 
that CAFs constitutively express the B7H1 and B7DC molecules 
(15) and their blocking completely restores activation of tumor-
associated T cells.
3Lo Presti et al. γδ T Cells and TME
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1395
Moreover, CAFs shows a direct function on the orchestration 
of TME, inducing preferentially T  cell apoptosis and Tregs; in 
fact the production of IL-6, CXCL8 are responsible for tumor-
associated macrophage (TAM) polarization toward M2 mac-
rophage polarization and functions during the differentiation 
of circulating monocytes to TAMs (16–19) while TGF-β induce 
the recruitment of macrophages at the tumor site, promoting the 
effective tumor evasion of the host immune system (20, 21).
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells play several protumoral func-
tions promoting tumor cell survival, angiogenesis, invasion of 
tumor cells, and initiation of metastasis formation (22). Moreover, 
they can directly and indirectly skew the immune response toward 
immune suppressive counterparts, using different strategies:
 (1) MDSCs are able to inhibit T cell proliferation and activation 
by (i) the depletion of essential amino acids such as l-arginine, 
via arginase-1 (ARG)-dependent consumption, and l-cystein 
by sequestering, as demonstrated in renal adenocarcinoma 
(23, 24); (ii) the reduction of local tryptophan levels and 
production of cytotoxic metabolites by indoleamine 2,3 
dioxygenase (IDO) (25); and (iii) the decrease of IL-2 pro-
duction and inhibition of the IL-2 receptor signaling, by the 
reactive oxygen and nitrogen species NO, ROS, H2O2, and 
peroxynitrite, produced by arginase 1 (Arg-1), nitric oxide 
synthase (iNOS), and NADPH oxidase (NOX2) (26, 27).
 (2) MDSCs induce T  cell apoptosis by several mechanisms, 
such as decrease of Bcl-2 expression and upregulation of 
FAS (CD95 ligand) in T cells, expression of galectin 9, which 
binds the inhibitory surface molecule TIM3 (T-cell immu-
noglobulin domain and mucin domain) and by expressing 
inhibitory surface molecules that alter T  cell viability and 
trafficking.
 (3) MDSCs interfere with lymphocyte trafficking and viability 
through the downregulation of L-selectin (CD62L) on the 
surface of T  cells, by expression of ADAM17 (disintegrin 
and metalloproteinase domain 17) and they also interrupt 
the migration of CD8+ T cells to tumor sites by peroxynitrite 
modification of CCL2 (28, 29).
 (4) MDSCs promote the differentiation of CD4+ T  cells into 
Tregs both by direct cell–cell interactions (including CD40–
CD40L interactions) and the production of several cytokines 
(such as IL-10 and TGF-β) (30), and polarize TAMs toward 
the M2 phenotype (31).
Regulatory T Cells
In the TME, classic Tregs, as defined by expression of CD4, CD25, 
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4/CD152), 
the Forkhead Box P3 transcription factor (32, 33), and Helios 
(34), directly promote immune evasion and the formation of a 
pro-tumorigenic TME, and prompt the growth and metastasis 
of various malignant tumors such as lung, ovary, breast, and 
prostate (35). Tregs exert their immunosuppressive activity using 
different approaches: they release soluble inhibitory molecules 
as TGF-β, IL-10, adenosine, PGE2, interfere with T effector cell 
activity and perforin/granzyme-mediated direct cytotoxicity by 
sequestration of IL-2 (36) and directly inhibit effector T cells by 
virtue of immune checkpoints and inhibitory receptors (CTLA-4, 
PD-1, and LAG-3) (37, 38).
M2 Macrophages
In the TME, macrophages typically differentiate to the M2 pheno-
type under the action of Th2 cytokines (such as IL-4 and IL-13) 
and glucocorticoids. M2 macrophages promote tumor growth 
by suppressing immune response, remodeling the extracellular 
matrix, and stimulating neoangiogenesis (39). The majority of 
macrophages that are recruited at the tumor site, called TAMs, 
acquire features closely similar to the M2 phenotype due to 
different stimuli present in the TME, such as IL-4 and TGF-β, 
accompanied by reduced antitumoral activity (40). TAMs play 
an important role for lymphangiogenesis through the release of 
VEGF-C and VEGF-D via VEGFR3, and neo angiogenesis by 
VEGF, TNF-α, CXCL8, PDGF-β, MMP2, MMP7, and MMP9, 
both of mechanism are critical steps for tumor growth, invasion, 
and metastasis (41).
eFFeCTS OF THe TMe ON γδ T CeLLS
γδ T cells are considered as good candidates for effective antitu-
mor immunotherapeutical approaches for their unique features as 
(i) the recognition of antigens shared by a variety of stressed and 
tumor cells (42) in the absence of major histocompatibility com-
plex (MHC) restriction and co-stimulation, (ii) the production of 
cytokines with well-known antitumor effect as IFN-γ and TNF-α 
with cytotoxic activity against tumor cells directly and indirectly 
via stimulating macrophages and DCs (43–45), and (iii) the potent 
cytotoxic activity in vitro and in xenograft models in vivo mediated 
by several different effector mechanisms (46–48). Moreover, γδ 
T  lymphocytes are recruited in several types of cancer (49) and 
analysis of expression signatures from a large number of human 
tumors identified them as the most significant favorable cancer-
wide prognostic signature for outcome (50, 51). Moreover, data 
mining transcriptomes from a large cohort of colorectal cancer 
patients (n =  585) has revealed that the aboundance of tumor-
infiltrating γδ T cells is related with the 5-year disease-free survival 
probability (51).
There are at least three major γδ T cell subsets in humans that 
exhibit different Vδ chain in the TCR: (1) the population express-
ing the Vδ2 gene paired with the Vγ9 chain (Vγ9Vδ2 T  cells) 
represent the majority of circulating γδ T cell population; (2) the 
population expressing the Vδ1 gene and different Vγ chain, are 
confined to skin and mucosa; and (3) a third subset of Vδ3 cells 
are present in higher percentage in the liver (52).
Antigen recognition by γδ T  cells is a field of intense 
research. Vδ1 T cells recognize MHC class I-related molecule A 
(MICA), MHC class I-related molecule B (MICB), and UL16-
binding proteins, expressed on stressed and tumor cells (53–55), 
glycolipid presented by MHC-related class Ib molecules CD1c 
and CD1d (56, 57), and unidentified ligands that engage natural 
cytotoxicity receptors (such as NKp30 and NKp44) (58). It is 
known that Vδ3 T cells can be activated by a glycolipid bound 
to CD1d molecules, but the real activating ligand are not yet 
defined (59).
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Finally, Vδ2 T  cells recognize non-peptidic phosphorylated 
intermediates of the non-mevalonate and mevalonate pathways 
of isoprenoid biosynthesis called phosphoantigens (PAgs), in the 
absence of processing, presentation, and MHC restriction (60).
Thus, there is a substantial interest in γδ T cells in the context 
of immunotherapeutic strategies, considering the intracellular 
accumulation of isopentenylpyrophosphate leading to activation 
of Vδ2 T  cells can be manipulated in the experimental assay 
and applied in vitro and in vivo cancer immunotherapy by two 
synthetic drugs, the synthetic PAg analog bromohydrin pyropho-
sphate and the aminobisphosphonate (n-BP) Zoledronate.
Nonetheless, recent flow cytometry or immunohistochemical 
studies of tumor-infiltrating γδ T  cells have failed to provide 
clear-cut evidence that they correlate positively or not with tumor 
growth, or even fail to correlate with any prognostic feature in 
different types of cancer, as reviewed in Ref. (61).
The dual role of Vδ2 T cells against tumor cells, either anti-
tumoral or protumoral, could be related to the plasticity of γδ 
T  cells to differentiate into different functional subsets under 
precise polarizing conditions; thus, Vδ2 T  cells may display 
Th1-, Th2- (62), Th9- (63), Th17- (64), or Treg-like (65) profiles 
and they can produce several immunosuppressive cytokines as 
TGF-β and IL-10. Recent papers indicate that IL-17 produced by 
Th17-like γδ T cells can directly promote the proliferation and 
dissemination of tumor cells in breast cancer (66–68) and in the 
TME IL-17 regulates other cell population, such as MDSCs and 
macrophages influencing indirectly the tumor immunosurveil-
lance (69). Treg-like Vδ2 T cells participate in the immunosup-
pressive TME either by the release of soluble molecules and 
by cell-to-cell contact via CD86/CTLA-4 and PD-L1/PD-1 
interactions (70, 71). Recently Hu et al. have identified a novel 
γδ Treg subset exhibiting CD39 expression that is polarized by 
TGF-β, with stronger immunosuppressive potential than CD4+ 
Tregs and that suppresses the activity of human lymphocytes in 
an adenosine-dependent manner (72).
This plasticity of γδ T cells and the plausible idea that the TME 
drives their differentiation toward subsets equipped with immu-
nosuppressive activities suggests the possibility that the TME can 
limit the effectiveness of the antitumor activity of γδ T cells (73).
How does then the TME induce the polarization of γδ T cells 
toward pro tumoral subsets?
Tumor cells and other cells of the TME produce inhibitory 
molecules which interfere with the proliferation and function 
of γδ T cells, such as TGF-β (74), prostaglandin-E2, adenosine 
(75, 76), and soluble NKG2D ligands (such as MICA/B) (77).
We have recently investigated the nature of the immunosup-
pressive soluble molecules present in secretomes from two differ-
ent human cancer types. We first analyzed secretomes obtained 
from cancer stem cells (CSC) and CAF of non-melanoma skin 
cancer patients, and found that the secretome of SCC patients 
contains cytokines (IL-6, IL-1β, IL-23, and TGF-β) capable of 
polarizing the differentiation of γδ17 T cells (78, 79), confirm-
ing the transition from IFN-γ-producing to IL-17-producing γδ 
T cells in the TME, during tumor progression observed in these 
patients. Whether or not these cytokines alone are responsible 
for the polarization toward γδ17 T cells or additional cells/factors 
are required is currently under investigation: accordingly, we 
have recently found that activated plasmacytoid dendritic cells 
provide yet unknown signals which selectively induce γδ17 T cell 
polarization of Vγ9Vδ2 T cells (80), which was dominant over the 
PAg-induced IFN-γ response.
In a second study, we have also studied the immunosuppressive 
properties of secretomes of CAF and CSC obtained from CRC 
patients (51). Secretome from colon CSCs significantly inhibits 
proliferation and IFN-γ production by freshly γδ T cells and also 
by γδ, CD4+, and CD8+ αβ T cell lines and promotes production 
of IL-17. Conversely, secretome from CAF has limited suppres-
sive ability and does not promote production of IL-17. Detailed 
analysis of CSC and CAF secretomes revealed only three cytokines 
differentially expressed by the inhibitory CSC secretome, but 
absent in the non-inhibitory CAF secretome, IL-8, IL-12, and 
VEGF. Because IL-12 does not have inhibitory activity on T cell 
proliferation and IFN-γ production, IL-8 and VEGF remain 
potential candidates of the immunosuppressive activities of the 
colon CSC secretome, which is probably not exerted directly on 
T cells but is rather mediated by other cell types like MDSCs, M2 
macrophages, DCs, and Tregs (81, 82).
While the above findings indicate that soluble molecules pre-
sent in the TME promote γδ T polarization to subvert antitumor 
immune response, it is likely that additional signals like prosta-
glandins (83), kynurenins (84), or potassium (85), are needed to 
achieve this effect.
Indeed, relating to the well-known ability of cancer cells to 
use inhibitory checkpoints to induce T cells apoptosis or anergy, 
Vδ2 T cells results not to be affected by this immunosuppressive 
mechanisms by the very low expression of PD-1 compared to 
conventional αβ CD8 and CD4 T cells; a recent paper have demon-
strated that upon 4 days of in vitro stimulation by Zoledronate 
and IL-2, Vδ2 T cells increase the expression of PD-1 but very 
rapidly decrease nearly to baseline (86) as well as TIGIT that 
is another negative checkpoint receptor (Hayday, unpublished 
results). Moreover, several suppressive cells in the TME can inhibit 
the proliferation and cytotoxic effect of γδ T cells (87–90). For 
example, tumor cells promote γδ T  cells polarization toward a 
Treg phenotype, that obstacle antitumor immunity (73), contri-
buting to the immunosuppressive microenvironment that is 
characteristic of most tumor cells as breast cancer (91). Deficient 
γδ T cell functions have already been observed in various types 
of cancer, including hematological malignancies (92), liver, breast 
cancer (93), and HCC (94).
TARgeTiNg TMe FOR THeRAPY
Cancer immunotherapy is a highly promising new cancer treat-
ment, that enhances the host antitumor response, increasing the 
number of effector immune cells, reducing host immunosuppres-
sive mechanisms, inducing tumor killing, and modulating immune 
checkpoints (93).
Better knowledge on how tumor cells escape immune response 
has been translated into innovative therapeutic strategies that 
redirect immune cells to tumors and restore their cytotoxic activity 
against tumor cells.
γδ T cell immunotherapy, either by the use of in vivo expanded 
T  cells by administration of compounds that activate them or 
FigURe 2 | Targeting tumor microenvironment for immunotherapy. Novel therapeutical approaches to improve γδ T cells-based immunotherapy: (A) inhibitory 
immunological checkpoint and bispecific antibodies, (B) chemotherapy, (C) liposomes, and (D) chimeric antigen receptor-T cells (CAR-T).
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by the adoptive transfer of ex vivo-activated γδ T cells, has been 
shown to be both feasible and safe (95).
However, there are technical and functional limitations to 
its use in cancer therapy; technical problems could be linked 
to the hyporesponsivness of γδ T cells in some patient or to the 
activation-induced γδ T cell anergy (lack of γδ T cell activation 
or expansion), while functional limitations could be related to the 
ability of in vivo or in vitro-expanded γδ T cells to reach and infil-
trate tumors and to defeat the immunosuppressive environment 
(90, 96). To overcome this limitations, several immunotherapeu-
tical approaches have been studied (Figure 2), we will discuss in 
the following sections.
inhibitory immunological Checkpoint
Combination of γδ T cell adoptive transfer with immune check-
point inhibitors is a useful strategy to enhance the antitumor 
activity of these cells.
The cancer immunotherapy has obtained an important pro-
gress by the use of therapeutic antibodies to CTLA-4, PD-1, and 
PD-L1 that antagonize immune checkpoints even though not all 
cancers respond to these antibody therapies. The pharmaceutical 
industries are involved in the development of new monoclonal 
antibodies that target B7H1 (PD-L1) (97, 98), considering that 
the blockade of B7H1 seems to induce durable tumor regression 
and prolonged disease stabilization in patients with advanced 
cancers in a phase I trial (99). Vγ9Vδ2 T cells express very low 
levels PD-1 compared to CD8 and CD4 T  cells, with a peak at 
4 days of in vitro activation with Zoledronate and IL-2 but it is 
not durable considering their rapid decrease upon 7 days reaching 
the baseline level [(86) and our unpublished data]. Beyond PD-1, 
many other immune checkpoint inhibitors as CTLA-4, IDO, 
VISTA, galectin-9, LAG-3, and TIM-3 should be investigated to 
improve γδ T cell adoptive immunotherapy.
Chemotherapy
Some cytotoxic compounds, including doxorubicin and oxaliplatin, 
can trigger “immunogenic” cell death. These chemotherapeutic 
agents act on tumor cells in such a way that the host immune 
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system recognizes the dying tumor cell. A tumor-specific immune 
response occurs during cell death, which results in an antitumor 
immune response leading to tumor eradication and prevention 
of relapse. This immunogenic cell death can prevent immune 
tolerance to tumor cells and is a crucial component of treatment 
efficacy (100). γδ T cells can be recruited to the tumor site after 
exposure to immunogenic chemotherapy and can contribute to 
its efficacy (67). In vitro, pre-treatment with low concentrations 
of chemotherapeutic agents (doxorubicin, cisplatin, etoposide, 
and vincristine) or even Zoledronate has been shown to sensitize 
tumor cells to killing by γδ T cells with additive or synergistic 
effects (101–104).
Therefore, such new effective immunotherapeutic approaches 
include the use of chemotherapeutic drugs that induce immuno-
genic cell death (100) or non-specific immune stimulation by 
cytokines such as IL-2 and IFN-α, monoclonal antibodies, and 
other biomolecules. Novel regimens that combine these drugs 
with PAgs or with γδ T cells are currently under investigation.
Liposomes
Aminobisphosphonates (N-BPs) have been shown to have anti-
cancer activity both as a monotherapy and in combination with 
γδ T cells. Due to the biodistribution of N-BPs in vivo, encapsula-
tion of N-BPs in a nanoformulation is a good technique for their 
use in the treatment of non-osseous tumors.
Liposomes, a closed bilayer phospholipid system, have been 
proposed as drug carriers in cancer therapy due to their abil-
ity to be preferentially taken up in tumors (105), to increase 
the therapeutic index of a drug and to reduce the side effects 
(106, 107). Moreover, nanoparticles such as liposomes pass very 
easily trough the blood vessel, expecially the neovessels inside 
the tumor that exhibit leaky endothelial lining. This effect is 
further reinforced by the lack of efficient lymphatic drainage of 
the tumor which causes liposomes to accumulate preferentially 
in the tumor area. This is known as enhanced permeation and 
retention effect (EPR) (108). Particles of 10–500 nm are thought 
to be able to extravasate into tumors as the pore sizes in the 
endothelial lining of leaky blood vessels in peripheral tumors 
are estimated to be 400–600  nm in diameter (109). However, 
particles with diameters <200 nm have been shown to be more 
effective at accumulating at tumor sites. This passive tumor tar-
geting does not occur in all tumors and vessel leakiness may also 
be heterogeneous within a single tumor (110). Ligand-targeted 
or “active” targeting of liposomes may result in liposomes that 
are more selective to cancer cells, once passive targeting has 
taken place (107).
Toxic side effects have been observed in vivo when Zoledronate 
and Alendronate were encapsulated into liposomes even though 
liposome-encapsulated (L)-Alendronate was shown to be better 
tolerated than L-Zoledronate. Hodgins and colleagues have 
obtained promising results using in vivo L-Alendronate and γδ 
T cells for the treatment of experimental metastatic lung tumors 
in immunocompromised mice (110).
To increase the uptake of L-Alendronate by receptor-mediated 
endocytosis in  vivo, Hodgins and colleagues have targeted 
L-Alendronate to the αvβ6 integrin receptor, which is overex-
pressed on cancer cells but absent on normal cells; combining 
the immunotherapy with γδ T  cells, they achieved substantial 
sensitization of αvβ6 positive cancer cells to γδ T cells and a more 
efficient cell killing in vitro. Despite the promise of using targeted-
L-Alendronate in a monotherapy regimen, no added advantage 
was observed in an experimental metastatic lung mice model by 
the combination of targeted-L-Alendronate and γδ T cells (111).
Bispecific Antibodies
The immunotherapeutical approaches using monoclonal anti-
body-based targeted therapy have obtained promising results, 
improved by the generation of bispecific antibody (bsAb) (112) 
capable of targeting multiple molecules as a single agent, even 
though the positive effects are not time durable because of their 
toxicity and cellular resistance mechanisms.
In order to be able to recruit and activate all T-cell subsets, 
most bsAbs target CD3, but as a consequence a wide range of 
T cells, including CD4+, CD8+, γδ T-cells, and also several immu-
noregulatory and immunosuppressive T-cell subsets are recruited.
Bispecific antibodies are very promising tools for γδ T cell-based 
immunotherapy with a lot advantages. There exist Vδ2γδT cell 
and γδ T cell (Vδ2 and Vδ1)-NK cell-specific bsAb which drasti-
cally enhance cytotoxic activity of these cells and did not recruit 
immunosuppressive γδ T cells (113–116).
Recently, de Bruin and colleagues produced a new bispecific 
nanobody that simultaneously targets Vγ9Vδ2 T cells and EGFR. 
This compound has shown a potent ability to activate Vγ9Vδ2 
T  cells and to induce their antitumoral activity in  vitro and in 
mouse xenograft model in vivo independently on the mutational 
status of the tumor. Thanks to the conserved monomorphic 
nature of the Vγ9Vδ2 TCR that permits a more selective cell 
recruitment, this immunotherapeutic approach could be used in 
several different clinical settings and could be applied to a large 
group of cancer patients (117).
Chimeric Antigen Receptor-T Cells 
(CAR-T)
Chimeric antigen receptors (CARs) redirect T cell specificity to 
tumor-associated antigens (TAAs), such as CD19, independently 
on the genetic (MHC) restriction.
Given the natural recruitment of γδ T cells for the tumor site, 
their transduction with CARs might increase their cytotoxic acti-
vity without affecting their migratory capability toward the tumor 
and their polarization toward antigen-presenting cells phenotypes 
that prolong the intratumoral immune response (118).
γδ T  cells directly recognizes unique TAAs, e.g., MICA/B, 
F1-ATPase, and PAgs, which are widely expressed by a variety of 
tumor cells (119) and thus, broad recognition of tumor cells and 
antitumor activities may be achieved by these T cells expressing a 
diverse γδ TCR repertoire.
The question concerning the optimization of the immuno-
therapeutical approaches using costimulatory molecules remains 
open and the synergy between TCR γδ and costimulatory mol-
ecules signals should be better explored for clinical expansion of 
Vδ2 T cells.
It is well known that γδ T cells express a series of costimulatory 
molecules such as CD27, CD28, and 4-1BB (CD137) that increase 
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their activation and effector function. Ribot et  al. showed that 
CD28 is constitutively expressed on γδ T cells and play a role on 
the survival and proliferation via IL-2 production (120). deBar-
ros and colleagues have shown the key role of CD70 molecule 
(CD27 ligand) on the in vitro expansion of Vγ9Vδ2 T cell by pro-
moting the upregulation of Cyclin D2 and the anti-apoptotic gene 
regulator Bcl2a1, and on the effector function by the production 
of high levels of IFN-γ (121). Another costimolatory molecule 
investigated on Vγ9Vδ2 T cells was CD137L that is expressed at 
high levels when cells are activated and act as a ligand for CD137 
on T and NK cells (122).
Capsomidis et al. have produced a new CAR by GD2-targeting, 
easily trasduced by both Vδ1 and Vδ2 subsets; the transduced 
cells have shown an increase cytotoxicity activity toward GD2-
expressing cancer cell lines, a stable ability to migrate in tumor 
cells, take up tumor antigens and cross-present the processed 
peptide to responder αβ T lymphocytes (118).
Although these engineered immune cells have made remark-
able success in the treatment of patients with hematologic malig-
nancies, the therapeutic efficacy in solid tumors has been limited 
because of the complexity and the heterogeneity of TME.
CONCLUSiON
Recent advances in cancer immunotherapy have revolutionized 
treatment for a number of cancers. By targeting checkpoint 
receptors, durable remissions have been achieved in patients with 
advanced metastatic melanoma, NSCLC, bladder cancer, and kid-
ney cancer, that otherwise would have had little chance of survival 
with conventional chemotherapies or targeted therapies. Similarly, 
CAR-T, bearing receptors specific for CD19 have successfully 
treated patients with relapsing B cell acute lymphoblastic leukemia 
and diffuse large B cell lymphoma. However, both these treatments 
have limitations. Therefore, additional types of immunotherapy 
are needed to achieve the full potential of cancer immunotherapy. 
Harnessing γδ T  cells toward tumor cells remains a fascinating 
immunotherapeutical approach, considering that their activation 
is not dependent on peptides presented by MHC proteins and 
is, therefore, MHC unrestricted. Finally, the efficacy of adoptive 
immunotherapy with Vδ2 T cells is independent of the mutational 
status of the tumor (123, 124), a limit for the efficacy of checkpoint 
blockade, and consequently could be also applied to patients with 
cancers that have low numbers of mutations, such as many of the 
pediatric cancers.
The well-known plasticity of γδ T  cells upon interaction 
with TME limits the effectiveness of this therapy, even though 
the overall interactions of the cells in TME and their rapid 
modifications induced by the natural story of the tumor and 
of the host remain an enigmatic story. A better comprehension 
of these mechanisms will be useful to formulate really efficient 
and durable therapeutic strategies that combine different appro-
aches and could restore antitumor immune responses, overcome 
tumor escape, and overcome tumor-induced immune deviation 
to enable the host immune system to more effectively control 
tumor growth.
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